A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

Learn about common-over-the-counter (OTC) treatments for migraine attacks, including acetaminophen and NSAIDs such as aspirin ...

TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine ...

Expert Rev Clin Pharmacol. 2013;6(3):271-288. All FDA-approved migraine treatments are approved only for adults. No migraine products have officially been approved for use in children. Other types ...

Treatment Consideration in Special Populations Migraine & Pregnancy Studies indicate a decreased frequency of headache activity (57%) in the first trimester and 85% in the second/third trimester ...

Posted: June 20, 2025 | Last updated: June 20, 2025 Anne-Marie Alexander, of Canfield, Ohio, social media campaign Shades for Migraine aims to raise awareness for migraine sufferers.

Migraine sufferers find relief with new treatment options by: Jakob Butler, Gretchen Bolander Posted: Jun 19, 2025 / 04:56 PM CDT Updated: Jun 20, 2025 / 09:30 AM CDT ...

Migraine is characterized by pulsating headaches, photophobia, vomiting, nausea and increased sensitivity to sound. Migraine is the leading cause of disability in people between the ages of 16 and 50.

AbbVie has announced that its Phase III TEMPLE study, which compared the oral calcitonin gene-related peptide (CGRP) receptor antagonist, atogepant, to topiramate’s highest tolerated dose for migraine ...

64.1% of atogepant users saw migraine days cut by half, compared to 39.3% for topiramate. Market-moving news hits Benzinga Pro first—get a 30-minute edge and save 60% this 4th of July. Add Comment ...

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention ...

NORTH CHICAGO, Ill., June 18, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study ...